Lymphoma Clinical Trials in Houston

Showing 381-400 of 467 trials

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

NCT01284192

This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).

Advanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROS+2 more

Astellas Pharma Inc46 participantsStarted Dec 2010

Orange, California, United States • Sacramento, California, United States • Chicago, Illinois, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

NCT00904722

The goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma. The safety of this drug combination will also be studied.

Lymphoma

M.D. Anderson Cancer Center32 participantsStarted Jan 2010

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

NCT01599949

The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.

Mantle Cell Lymphoma

Janssen Research & Development, LLC120 participantsStarted Aug 2012

La Jolla, California, United States • Los Angeles, California, United States • Stanford, California, United States +53 more locations

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Lymphoma Trials in Other Cities

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Other Conditions in Houston